Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives

References

• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381:2020–2031. doi:10.1056/nejmoa1910231
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801. doi:10.1056/NEJMOA1802357
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828. doi:10.1016/S0140-6736(20)32531-9
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758. doi:10.1158/1078-0432.CCR-18-4070
   PubMed Web of Science ®Google Scholar
• André T, Shiu -K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi:10.1056/NEJMOA2017699
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–249. doi:10.1146/ANNUREV-PATHOL-042020-042741
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Wang R, Singaraju A, Marks KE, et al. Clonally expanded CD38. 2021.
   Google Scholar
• Chan KK, Tirpack A, Vitone G, et al. Higher checkpoint inhibitor arthritis disease activity may be associated with cancer progression: results from an observational registry. ACR Open Rheumatol. 2020;2(10):595–604. doi:10.1002/ACR2.11181
   PubMedGoogle Scholar
• Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2019;79:332–338. doi:10.1136/annrheumdis-2019-216109
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Bingham CO, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 2017;69(11):1751–1763. doi:10.1002/ACR.23177
   PubMed Web of Science ®Google Scholar
• Arnaud-Coffin P, Maillet D, Gan HK, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. 2019;145(3):639–648. doi:10.1002/IJC.32132
   PubMed Web of Science ®Google Scholar
• Richter MD, Crowson C, Kottschade LA, et al. Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Ann Rheum Dis. 2019;17(3):1–10. doi:10.1007/s00262-017-2069-9
   Web of Science ®Google Scholar
• Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer. Arthritis Rheumatol. 2022;74(3):527–540. doi:10.1002/ART.41949/ABSTRACT
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology. 2019;58(3):476–478. doi:10.1093/RHEUMATOLOGY/KEY358
   PubMed Web of Science ®Google Scholar
• Ghosh N, Tiongson MD, Stewart C, et al. Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series. J Clin Rheumatol. 2021;27(8):E317–E322. doi:10.1097/RHU.0000000000001370
   PubMed Web of Science ®Google Scholar
• Calabrese C, Cappelli LC, Kostine M, Kirchner E, Braaten T, Calabrese L. Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open. 2019;5(1):e000906. doi:10.1136/rmdopen-2019-000906
   PubMed Web of Science ®Google Scholar
• Martin De Fremont G, Belkhir R, Henry J, et al. Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy. Ann Rheum Dis. 2022;81(3):E52. doi:10.1136/annrheumdis-2020-217225
   PubMed Web of Science ®Google Scholar
• Reid P, Liew DFL, Akruwala R, Bass AR, Chan KK. Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study. J Immunother Cancer. 2021;9(9). doi:10.1136/JITC-2021-003260
   Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events (CTCAE) v5.0; 2017. Available from: https://www.meddra.org/. Accessed January 15, 2022.
   Google Scholar
• Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. 2012;64(5):640–647. doi:10.1002/ACR.21649
   PubMed Web of Science ®Google Scholar
• Bruce B, Fries JF. The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20. doi:10.1186/1477-7525-1-20
   PubMedGoogle Scholar
• Ghosh N, Chan KK, Jivanelli B, Bass AR, Ayaz NA. Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors. J Clin Rheumatol. 2021;27:1–8. doi:10.1097/rhu.0000000000001777
   PubMed Web of Science ®Google Scholar
• De Moel EC, Rozeman EA, Kapiteijn EH, et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol Res. 2019;7(1):6–11. doi:10.1158/2326-6066.CIR-18-0245
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Darrah E, Shah AA, Bingham CO. Patients with checkpoint inhibitor‐induced inflammatory arthritis do not become seropositive for anti‐cyclic citrullinated peptide when followed over time. ACR Open Rheumatol. 2022;4(1):83–84. doi:10.1002/acr2.11363
   PubMedGoogle Scholar
• Subedi A, Williams SG, Yao L, et al. Use of magnetic resonance imaging to identify immune checkpoint inhibitor-induced inflammatory arthritis. JAMA Netw open. 2020;3(2):e200032. doi:10.1001/JAMANETWORKOPEN.2020.0032
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43–50. doi:10.1136/annrheumdis-2016-209595
   PubMed Web of Science ®Google Scholar
• Van Der Geest KSM, Sandovici M, Rutgers A, et al. Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica. Ann Rheum Dis. 2020;1–2. doi:10.1136/annrheumdis-2020-217381
   Web of Science ®Google Scholar
• Medina H, Eickhoff J, Edison J. Thinking inside the box. J Clin Rheumatol. 2019. doi:10.1097/RHU.0000000000001088
   PubMedGoogle Scholar
• Murray-Brown W, Wilsdon TD, Weedon H, et al. Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. J Immunother Cancer. 2020;8(1):1–6. doi:10.1136/jitc-2019-000281
   Web of Science ®Google Scholar
• Wang R, Singaraju A, Marks KE, et al. Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis. bioRxiv. 2021. doi:10.1101/2021.10.19.464961
   Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–829. doi:10.1056/NEJMOA1604958/SUPPL_FILE/NEJMOA1604958_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Murray K, Floudas A, Murray C, et al. First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis. BMJ Case Rep CP. 2021;14(2):e238851. doi:10.1136/BCR-2020-238851
   PubMedGoogle Scholar
• Belkhir R, Le Burel S, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76(10):1747–1750. doi:10.1136/annrheumdis-2017-211216
   PubMed Web of Science ®Google Scholar
• Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412. doi:10.1136/rmdopen-2016-000412
   PubMed Web of Science ®Google Scholar
• Leipe J, Christ LA, Arnoldi AP, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018;4(2):1–7. doi:10.1136/rmdopen-2018-000714
   Web of Science ®Google Scholar
• Roberts J, Smylie M, Walker J, et al. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis. Clin Rheumatol. 2019;38(5):1513–1519. doi:10.1007/s10067-019-04451-2
   PubMed Web of Science ®Google Scholar
• Smith MH, Bass AR. Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res. 2017. doi:10.1002/acr.23467
   Web of Science ®Google Scholar
• Lee J, Graham A, Sion A. Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract. 2019;25(8):1867–1872. doi:10.1177/1078155218822707
   PubMed Web of Science ®Google Scholar
• Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17(3):284–289. doi:10.1016/j.autrev.2018.01.003
   PubMed Web of Science ®Google Scholar
• Mooradian MJ, Nasrallah M, Gainor JF, et al. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. Semin Arthritis Rheum. 2019;48(6):1127–1132. doi:10.1016/j.semarthrit.2018.10.012
   PubMed Web of Science ®Google Scholar
• Verspohl SH, Holderried T, Behning C, Brossart P, Schäfer VS. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Ther Adv Musculoskelet Dis. 2021;13:1–14. doi:10.1177/1759720X211006963
   Web of Science ®Google Scholar
• Mitchell EL, Lau PKH, Khoo C, et al. Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer. 2018;105(2018):88–102. doi:10.1016/j.ejca.2018.09.027
   PubMed Web of Science ®Google Scholar
• Van Der Geest KSM, Sandovici M, Rutgers A, et al. Management of immune checkpoint inhibitor-induced polymyalgia rheumatica. Ann Rheum Dis. 2020;1–2. doi:10.1136/annrheumdis-2020-218276
   Web of Science ®Google Scholar
• Ceccarelli F, Botticelli A, Gelibter AJ, et al. Correspondence on “Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation” by Braaten et al. Ann Rheum Dis. 2022;81(1):1–2. doi:10.1136/annrheumdis-2019-216867
   Web of Science ®Google Scholar
• Buder-Bakhaya K, Benesova K, Schulz C, et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 2018;67(2):175–182. doi:10.1007/s00262-017-2069-9
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Brahmer JR, Forde PM, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018;48:1–5. doi:10.1016/j.semarthrit.2018.02.011
   PubMed Web of Science ®Google Scholar
• Roberts J, Ennis D, Hudson M, et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev. 2020;19(8):102595. doi:10.1016/j.autrev.2020.102595
   PubMed Web of Science ®Google Scholar
• Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer - Clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393–398. doi:10.1136/annrheumdis-2017-212257
   PubMed Web of Science ®Google Scholar
• Liu Y, Jaquith JM, Mccarthy-Fruin K, et al. Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis. Clin Rheumatol. 2020;39(12):3631–3637. doi:10.1007/s10067-020-05162-9
   PubMed Web of Science ®Google Scholar
• Ornstein MC, Calabrese C, Wood LS, et al. Myalgia and arthralgia immune-related adverse events (irAEs) in patients with genitourinary malignancies treated with immune checkpoint inhibitors. Clin Genitourin Cancer. 2019;17(3):177–182. doi:10.1016/j.clgc.2019.01.021
   PubMed Web of Science ®Google Scholar
• Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 2019;71(3):468–475. doi:10.1002/art.40745
   PubMed Web of Science ®Google Scholar
• Haanen JB, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Supplement 4):iv119–iv142. doi:10.1093/annonc/mdx225
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073–4126. doi:10.1200/JCO.21.01440
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines version 4.2021 management of immunotherapy-related toxicities NCCN guidelines panel disclosures continue NCCN; 2021. Available from: https://www.nccn.org/home/member-. Accessed December 18, 2021.
   Google Scholar
• Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. doi:10.1136/JITC-2021-002435
   PubMed Web of Science ®Google Scholar
• Kostine M, Finckh A, Bingham CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80(1):36–48. doi:10.1136/ANNRHEUMDIS-2020-217139
   PubMed Web of Science ®Google Scholar
• Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–166. doi:10.1038/S41584-020-0372-X
   PubMed Web of Science ®Google Scholar
• Choi J, Fenando A. Sulfasalazine. Intraocular Inflamm. 2021;373–377. doi:10.1007/978-3-540-75387-2_30
   Google Scholar
• Gerriets V, Bansal P, Goyal A, Khaddour K. Tumor necrosis factor inhibitors. StatPearls; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482425/. Accessed January 15, 2022.
   Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):16295–16296. doi:10.1101/CSHPERSPECT.A016295
   PubMed Web of Science ®Google Scholar
• Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706–3714. doi:10.1002/cncr.31629
   PubMed Web of Science ®Google Scholar
• Maslov DV, Tawagi K, Kc M, et al. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J Immunother Cancer. 2021;9(7):e002261. doi:10.1136/JITC-2020-002261
   PubMed Web of Science ®Google Scholar
• Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6(1). doi:10.1186/s40425-018-0346-6
   Web of Science ®Google Scholar
• Krueger J, Santinon F, Kazanova A, et al. Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. PLoS One. 2021;16(6):e0251731. doi:10.1371/JOURNAL.PONE.0251731
   PubMed Web of Science ®Google Scholar
• Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol. 2021;17(4):213–223. doi:10.1038/s41584-021-00584-4
   PubMed Web of Science ®Google Scholar
• Johnson DH, Zobniw CM, Trinh VA, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6(1). doi:10.1186/s40425-018-0412-0
   Web of Science ®Google Scholar
• Verheijden RJ, May AM, Blank CU, et al. Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res. 2020;26:2268–2274. doi:10.1158/1078-0432.ccr-19-3322
   PubMed Web of Science ®Google Scholar
• Zou F, Faleck D, Thomas A, et al. Original research: efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021;9(11):e003277. doi:10.1136/JITC-2021-003277
   PubMed Web of Science ®Google Scholar
• Stroud CRG, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25(3):551–557. doi:10.1177/1078155217745144
   PubMed Web of Science ®Google Scholar
• Dimitriou F, Hogan S, Menzies AM, Dummer R, Long GV. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur J Cancer. 2021;157:214–224. doi:10.1016/j.ejca.2021.08.031
   PubMed Web of Science ®Google Scholar
• Fa’ak F, Zobniw CM, Buni M, et al. Selective immune suppression using interleukin-6 blockade in immune related adverse events. J Immunother Cancer. 2021;9(Suppl 2):A853–A853. doi:10.1136/JITC-2021-SITC2021.816
   Web of Science ®Google Scholar
• Damuzzo V, Solito S, Pinton L, et al. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. Oncoimmunology. 2016;5(12):e1249559. doi:10.1080/2162402X.2016.1249559
   PubMed Web of Science ®Google Scholar
• Tachibana H, Nemoto Y, Ishihara H, et al. Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer. 2021;20:e81–e88. doi:10.1016/J.CLGC.2021.10.005
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu X, Du J, et al. Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. Thorac Cancer. 2022;13(2):219–227. doi:10.1111/1759-7714.14248
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Fujieda K, Miyashita A, et al. Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018;78(17):5011–5022. doi:10.1158/0008-5472.CAN-18-0118
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76(3):504–510. doi:10.1136/ANNRHEUMDIS-2016-209773
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Hellstern P, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2019;68(1):40–48. doi:10.1136/gutjnl-2017-314562
   PubMed Web of Science ®Google Scholar
• Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519. doi:10.2147/JIR.S219586
   PubMed Web of Science ®Google Scholar
• Salem J-E, Allenbach Y, Vozy A, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377–2379. doi:10.1056/NEJMC1901677
   PubMed Web of Science ®Google Scholar
• Tyan K, Baginska J, Brainard M, et al. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2021;70(8):2209–2221. doi:10.1007/s00262-021-02855-1
   PubMed Web of Science ®Google Scholar
• Husain B, Kirchberger MC, Erdmann M, et al. Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J Cancer Res Clin Oncol. 2021;147(6):1623–1630. doi:10.1007/S00432-021-03550-5
   PubMed Web of Science ®Google Scholar
• Esfahani K, Miller WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med. 2017;376(20):1989–1991. doi:10.1056/NEJMC1703047/SUPPL_FILE/NEJMC1703047_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Thomas AS, Ma W, Wang Y. Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med. 2021;384(6):581–583. doi:10.1056/NEJMC2031717
   PubMed Web of Science ®Google Scholar
• Deftereos SN, Georgonikou D. Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review. Ann Oncol. 2021;32(2):282–283. doi:10.1016/J.ANNONC.2020.12.001
   PubMed Web of Science ®Google Scholar
• Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 2019;5(9):1310–1317. doi:10.1001/JAMAONCOL.2019.1022
   PubMed Web of Science ®Google Scholar
• Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6(6):865–871. doi:10.1001/JAMAONCOL.2020.0726
   PubMed Web of Science ®Google Scholar
• van der Kooij MK, Suijkerbuijk KP, Dekkers OM, Kapiteijn E. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease. Ann Intern Med. 2021;174(9):1345. doi:10.7326/L21-0441
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168(2):121–130. doi:10.7326/M17-2073
   PubMed Web of Science ®Google Scholar
• Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–2878. doi:10.1200/JCO.2018.79.0006
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–376. doi:10.1093/annonc/mdw443
   PubMed Web of Science ®Google Scholar
• Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108. doi:10.1016/S0140-6736(10)60826-4
   PubMed Web of Science ®Google Scholar
• Ghosh N, Postow M, Zhu C, et al. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. J Immunother Cancer. 2022;10(1):e004008. doi:10.1136/jitc-2021-004008
   PubMed Web of Science ®Google Scholar